Q32 Bio Inc. (QTTB): Insider Trading, Congress Trades & Research | Tormere

QTTB

$8.71+3.08%visit website download financials (.py)

Q32 Bio Inc.

Market Cap

$259M

Live price × shares (2026-10-17)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.36

60mo monthly vs SPY

P/E (TTM)

7.7

TTM to Jun 2026 · mkt cap / net income

P/S (TTM)

4.8

Price / TTM revenue

P/B

2.4

Price / stockholders equity

EV/EBITDA

7.0

TTM

Price Chart

Loading…

Signals

Insider Velocity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

ORBIMED ADVISORS LLC · 2026-07-20

Analyst Consensus

Strong Buy

12 analysts

Velocity Score

9.22x

Avg Daily Selling (90d)

245 sh/day

Baseline Daily Selling

68.2 sh/day

Unique Sellers (90d)

3

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-10-06	2026-10-14	Violette Shelia M.	Chief Scientific Officer	Sale	917	$8.32	$8K	126.9K	View
2026-10-06	2026-10-14	Morrison Jodie Pope	Director & CEO	Sale	3,221	$8.32	$27K	340.0K	View
2026-10-06	2026-10-14	Kalowski Lee	CFO and President	Sale	1,301	$8.32	$11K	137.2K	View
2026-08-25	2026-08-27	Kalowski Lee	CFO and President	Sale	3,972	$16.56	$66K	138.5K	View
2026-08-25	2026-08-27	Morrison Jodie Pope	Director & CEO	Sale	9,845	$16.56	$163K	343.3K	View

1–5 of 11

1 / 3

Recent News

Q32 Bio Inc. Estimates – NASDAQ:QTTB

TradingView · 2026-10-23

Leerink Partners Initiates Coverage On Q32 Bio with Outperform Rating, Announces Price Target of $40

Benzinga · 2026-10-12

This Biotech Had Good News for Hair Loss Sufferers. So Why Is the Stock Sinking?

Yahoo · 2026-10-01

Oppenheimer reiterates Q32 Bio stock rating on durable trial data

Investing.com · 2026-10-01

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

Yahoo · 2026-09-30

Q32 Bio Announces Additional 36-Week Results And Initial Findings From The 16-Week Off-Drug Period From Part B Of The SIGNAL-AA Phase 2A Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe AA; Clinically Meaningful Efficacy Data Observed On Primary And Key Secondary Endpoints At Week 36; Robust Durability, Including Maintenance And Deepening Of Response

Benzinga · 2026-09-30

$QTTB stock is down 15% today. Here's what we see in our data.

Quiver Quantitative · 2026-09-30

Jefferies Initiates Coverage On Q32 Bio with Buy Rating, Announces Price Target of $29

Benzinga · 2026-09-28

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026

Yahoo Finance · 2026-09-21

Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer

Yahoo Finance · 2026-09-14

Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround

Yahoo Finance · 2026-09-07

Q32 Bio to Participate in Upcoming September Investor Conferences

Yahoo Finance · 2026-09-01

Q32 Bio: The Efficacy Is Modest, The Valuation Is Not (NASDAQ:QTTB)

Seeking Alpha · 2026-08-24

Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?

Yahoo Finance · 2026-08-17

Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice

Yahoo Finance · 2026-07-20

Informational purposes only, not investment advice.

Recent Insider Activity (Form 4) — Last 5

Date	Insider	Type	Shares	Value
2026-10-06	Violette Shelia M.	S	917	$7,629.16
2026-10-06	Morrison Jodie Pope	S	3,221	$26,798.08
2026-10-06	Kalowski Lee	S	1,301	$10,824.06
2026-08-25	Kalowski Lee	S	3,972	$65,776.32
2026-08-25	Morrison Jodie Pope	S	9,845	$163,033.2